ArticleData in brief2025
HER2-SISH40x: Annotated histopathology image dataset for HER2 amplification assessment in breast cancer.
Article in Data in brief, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Toward AI-Assisted Precision Diagnostics in Breast Cancer: Source-Group-Preserving Evaluation of Class-Imbalance Strategies for Ordered ER-IHC Segmentation.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The HER2 overexpression serves as a crucial biomarker in breast cancer diagnosis and treatment decision-making. In-situ hybridization (ISH) is widely employed for determination HER2 gene amplification. We introduce the HER2-SISH40x dataset based on VENTANA HER2 Dual probe ISH (DISH) staining, consisting of image patches curated from 50 whole slide images (WSIs) acquired at 40 × magnification using a 3DHistech Pannoramic DESK scanner. Expert pathologists annotated 237 regions of interest (ROIs) categorized as breast cancer with HER2 amplification (HER2/CEP17 >2 and HER2 signals/cancer cell >4), or breast cancer without HER2 amplification (HER2/CEP17 <2 and HER2 signals/cancer cell <4), with an additional 300 Normal ROIs extracted from both Amplified and Non-Amplified WSIs. This dataset is suitable for developing and evaluating computational pathology methods, particularly deep learning models for automated HER2 scoring, segmentation, and classification. The dataset has been successfully applied in several research studies [1-3], addressing challenges such as color normalization, cancer-region classification, and automated HER2 signal quantification. Research ethical clearance was obtained from the University Malaya Medical Center. The HER2-SISH40x dataset offers a valuable resource for advancing digital pathology workflows and personalized breast cancer diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.